GSK Transfers Products to Renaissance

Renaissance Acquisition Holdings, LLC, a RoundTable Healthcare Partners portfolio company, and GlaxoSmithKline have entered an agreement giving Renaissance the rights to manufacture, market and sell six GSK dermatology products and three anti-viral products in the U.S. The products will be marketed through Renaissance’s branded division Prestium Pharma. Renaissance owns DPT and Confab Laboratories.
 
The products from GSK and Stiefel, a GSK company, include: Evoclin Foam, 1%, Extina Foam, 2%, Luxiq Foam, 0.12%, Olux Foam, 0.05%, Olux-E Foam, 0.05%, Vusion Ointment, Zovirax Capsules, Zovirax Tablets, Zovirax Suspension.
 
Pierre Fréchette, president and chief executive officer of Renaissance, said, “This transaction represents a significant milestone for Renaissance, and is in line with our strategy of acquiring niche products that we can both manufacture within our internal network and market through our strong commercial group. The RoundTable team was instrumental in helping to source, diligence and complete such an important acquisition.”
 
Simon Jose, Stiefel’s president, said, “This agreement allows U.S. patients to continue to have access to treatments they value and allows the Stiefel U.S. team to focus on growth and development of new treatments within our core dermatology portfolio.”
 
Said John Denman, general manager of Prestium, “We are excited to add these mature specialty brands to Prestium’s growing portfolio, and look forward to continuing to supply such important products to our customers and to patients across the country.”